Every-Two-Weeks Diabetes Shot Works as Well as Weekly

What Was Studied — and Why It Matters

Taking a weekly injection is already a big improvement over daily insulin for many people with type 2 diabetes — but what if you only needed a shot every two weeks? Researchers tested a new GLP-1 receptor agonist called efsubaglutide alfa to see whether a larger dose given every two weeks could control blood sugar just as well as a smaller weekly dose. For patients who struggle with injection schedules or find weekly routines difficult, a biweekly option could be a genuine game-changer.

What the Researchers Did

This was a randomised, multicentre trial involving 59 adults with type 2 diabetes whose blood sugar was not adequately controlled by lifestyle changes alone. Half received efsubaglutide alfa 3 mg every two weeks, and the other half received 1 mg every week for 12 weeks. Participants wore continuous glucose monitors (CGMs) throughout, giving researchers a detailed, real-world picture of blood sugar patterns — not just a single snapshot number.

What They Found

• HbA1c dropped significantly in both groups. The every-two-weeks group saw an average drop of 1.45%, while the weekly group dropped 1.53% — a difference so small it is not considered clinically meaningful.
• Time in range improved dramatically. Both groups started with roughly 45% of their day in a healthy blood sugar range. By the end of the study, both groups were spending about 75–77% of their day in range — a major improvement.
• Fasting blood sugar fell similarly in both groups, dropping by just over 2 mmol/L.
• No dangerous low blood sugar (hypoglycaemia) occurred in either group, and no cardiovascular events were reported.
• Side effects were mainly mild digestive issues — such as nausea — common with GLP-1 medications and mostly manageable.

What This Means for Real Patients

If you or someone you care for finds it hard to maintain a weekly injection schedule, a biweekly option could meaningfully reduce that burden without sacrificing blood sugar control. Better time in range also means fewer spikes and crashes throughout the day — something a CGM device can help you track in real time. At MDS Diabetes, we carry a full range of CGM supplies and injection accessories that make managing a GLP-1 regimen easier, whether you're dosing weekly or every two weeks.

It is important to note this was a relatively small, short-term study. Larger trials in more diverse populations are still needed before this drug becomes widely available, but the early results are genuinely encouraging.

Bottom Line

Efsubaglutide alfa given every two weeks controlled blood sugar about as well as a weekly shot in people with type 2 diabetes. Time in range jumped from 45% to over 75% in both groups, with no serious low blood sugar events. A biweekly injection schedule could offer a more convenient and equally effective alternative for patients — though larger studies are needed to confirm these findings.